title: Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization.
abstract: BACKGROUND
  The aim of this retrospective, multicenter study was to compare high- versus standard-dose lenograstim after chemotherapy in collecting target dose of CD34+ peripheral blood progenitor cells (PBPCs) in adult candidates for autologous transplant.
  
  
  METHODS
  A total of 166 consecutive patients (28 acute leukemias [ALs], 77 lymphomas, 61 multiple myeloma [MM]) underwent 182 mobilization procedures. Only the first were analyzed. The CD34+ cell target was at least 2×10(6) , 4×10(6) , and 8×10(6) /kg and lenograstim started on days +19, +1, and +5 from the end of chemotherapy for AL, lymphomas, and MM, respectively. Eighty-seven and 79 patients, respectively, received 5 and 10µg/kg/day lenograstim subcutaneously (sc). An analysis to evaluate factors predicting satisfactory procedures and outcome of transplants performed with first-mobilization-procedure PBPCs was conducted. Most patients received 6mg of pegfilgrastim or 5µg/kg/day lenograstim sc after transplant.
  
  
  RESULTS
  In multivariate analysis, high-dose lenograstim (p=0.053) in MM and male sex (p=0.028) were positive predictive factors for reaching cell target. Fludarabine negatively influenced stimulation length (p=0.002). Apheresis, CD34+ cells mobilized and collected, blood volume processed, side effects, transplants performed, and engraftment time were similar between lenograstim cohorts. Pegfilgrastim versus lenograstim delayed platelet (PLT) recovery times (13 days vs. 11 days, p=0.036).
  
  
  CONCLUSIONS
  High-dose lenograstim more efficiently mobilized MM patients requiring the highest PBPC target but did not influence transplants performed and engraftment time. Male patients mobilized more efficiently. Fludarabine negatively influenced stimulation length. Finally, pegfilgrastim seems to delay PLT recovery.
authors.affiliation: Department of Hematology, Regina Elena National Cancer Institute, Rome, Italy. a.romeo@live.it
authors.forename: Azzurra
authors.initials: A
authors.lastname: Romeo
authors.forename: Anna
authors.initials: A
authors.lastname: Chierichini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Spagnoli
authors.forename: Mariangela
authors.initials: M
authors.lastname: Vittori
authors.forename: Michele
authors.initials: M
authors.lastname: Vacca
authors.forename: Maria
authors.initials: M
authors.lastname: Gozzer
authors.forename: Antonio
authors.initials: A
authors.lastname: Spadea
authors.forename: Barbara
authors.initials: B
authors.lastname: Anaclerico
authors.forename: Maria Laura
authors.initials: ML
authors.lastname: Dessanti
authors.forename: Mariella
authors.initials: M
authors.lastname: D'Andrea
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Toglia
authors.forename: Luciana
authors.initials: L
authors.lastname: Annino
authors.forename: Maria Concetta
authors.initials: MC
authors.lastname: Petti
authors.forename: Andrea
authors.initials: A
authors.lastname: Mengarelli
authors.forename: William
authors.initials: W
authors.lastname: Arcese
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D019337:Hematologic Neoplasms / Q000191:economics / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000191:economics / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D017721:Hospital Costs; D006801:Humans; D000078224:Lenograstim; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000078224:Lenograstim